New malaria vaccine dosing strategy tested in Early-Stage trial
NCT ID NCT06320535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether giving the R21/Matrix-M malaria vaccine in a new, escalating-dose schedule is safe and creates a strong immune response. It involves 36 healthy adults in the UK who have never had malaria. The goal is to find a better way to protect people from this serious disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Clinical Vaccinology and Tropical Meducine, Churchill Hospital, University of Oxford
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol, BS2 8HW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental malaria vaccine aims to block parasite growth
- New malaria drug interaction study launches in healthy volunteers
- New malaria shots could replace daily pills
- New malaria antibody enters first human safety tests
- Breastfeeding moms with malaria: do drugs reach baby?
- New malaria pill shows promise in early trial